Clinical trials: Metastatic Colorectal Neoplasms
Colon Cancer, Rectal Cancer
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects.
- Trial name
- NCT01347645
- Testing
- FOLFIRI, E7820
- Where
- 38 sites in United States, Argentina and 4 more
- Volunteers
- 82 people
- Sponsor
- Eisai Inc.
Colorectal Neoplasms
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
The primary objective of this study is to evaluate PFS rate at 9 months of BIBF 1120 in combination with mFolfox6 compared with mFolfox6 combined to bevacizumab in first line patients with metastatic colorectal cancer.
- Trial name
- NCT00904839
- Testing
- BIBF 1120, mFolfox, Bevacizumab
- Where
- 47 sites in Belgium, France and 3 more
- Volunteers
- 128 people
- Sponsor
- Boehringer Ingelheim
Incurable Metastatic Colorectal Carcinoma, Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 1 and 2 Study of PX-866 and Cetuximab
The purpose of this Phase 1/2 open-label study is to determine the safety and efficacy of a cetuximab and PX-866 combination treatment.
- Trial name
- NCT01252628
- Testing
- PX-866 (SCCHN), Cetuximab (SCCHN), PX-866 (CRC)
- Where
- 40 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- Cascadian Therapeutics Inc.
Colorectal Cancer
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
The purposes of this study are to determine whether administering escalating doses of cetuximab in patients with no early skin toxicity could delay the progression of disease in a significant proportion of patients and to study…
- Trial name
- Everest2 (NCT01251536)
- Testing
- Dose escalation of cetuximab, Standard first line treatment with cetuximab + Folfiri
- Where
- 30 sites in Austria, Belgium and 3 more
- Volunteers
- 108 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Colorectal Cancer
DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic…
- Trial name
- NCT00024401
- Testing
- DHA-paclitaxel
- Where
- 6 sites in United States
- Sponsor
- Theradex
Colorectal Cancer Metastatic
Effect of Age, Body Mass Index and Tumor Sidedness in Metastatic Colorectal Cancer
To determine progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer in relation to age, BMI and tumor sidedness, describing their predictive influence on systemic therapy outcome.
- Trial name
- NCT04543019
- Volunteers
- 50 people
- Sponsor
- Assiut University
Malignant Tumor of Small Intestine Metastatic to Liver
Study of TCM Syndrome of Hepatocellular Carcinoma and Colorectal Cancer Based on System Science
Traditional Chinese medicine (TCM) syndrome is a core foundation of disease knowledge, clinical diagnosis and treatment and curative effect evaluation in TCM.
- Trial name
- NCT03189992
- Testing
- Bushen-Jianpi Dedoction, cinobufotalin injection
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Colorectal Cancer
A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis.
Assuming that the objective response rate (ORR) of neoadjuvant chemotherapy in patients with colorectal cancer peritoneal metastasis is approximately 0.40 , a total sample size of 30 patients is required.
- Trial name
- NCT07268677
- Testing
- pirfenidone plus sintilimab combined with standard neoadjuvant chemotherapy
- Volunteers
- 30 people
- Sponsor
- Guoxiang Cai
Colorectal Cancer, Liver Metastases
ALPPS Versus PVE/PL
Study Title Comparison of two different models of liver growth stimulation in advanced colorectal liver metastatic disease, (LIGRO Trial) enabling liver resection Methodology Scandinavian Multiple Center Randomized Registry Based…
- Trial name
- LIGRO (NCT02215577)
- Testing
- In-situ split, Portal embolization or ligation
- Where
- 7 sites in Denmark, Norway and 1 more
- Volunteers
- 100 people
- Sponsor
- Regionalt Cancercentrum Väst
Resectable Simultaneous Colorectal Cancer Liver Metastasis
The Outcomes of Laparoscopic Hybrid Surgery Versus Totally Open Surgery
Simultaneous colorectal cancer liver metastasis (SCRLM) is one of the risk factors for poor prognosis in colorectal cancer. Surgical resection of primary and metastatic lesions is the first choice of treatment for patients with…
- Trial name
- NCT06550700
- Testing
- laparoscopic hybrid surgery (LHS)
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Changhai Hospital
Colorectal Cancer Stage IV, Lymph Node Yield
Prognostic Impact of Increased Lymph Node Yield in Colorectal Cancer Patients With Synchronous Distant Metastasis: a Population-based Study of the US Database and a Chinese Registry
The National Quality Forum has endorsed at least 12 lymph node yield (LNY) as a surgical quality indicator in colorectal cancer (CRC), but the prognostic value of adequate lymphadenectomy has rarely been investigated for CRC…
- Trial name
- NCT05550701
- Testing
- lymph node yield
- Where
- China
- Volunteers
- 4,575 people
- Sponsor
- The Second Affiliated Hospital of Harbin Medical University
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma
AB122 Platform Study
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
- Conditions
- Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04999761
- Testing
- AB122, TAS-116, TAS-120
- Where
- 9 sites in Japan
- Volunteers
- 917 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
- Trial name
- EVEREST-2 (NCT06051695)
- Testing
- A2B694, A2B543, xT CDx with HLA-LOH Assay
- Where
- 12 sites in United States
- Volunteers
- 474 people
- Sponsor
- A2 Biotherapeutics Inc.
Colorectal Cancer Metastatic
Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer
RAS genotyping is mandatory for the prescription of anti-EGFR (epidermal growth factor receptor) therapies in patients with metastatic colorectal cancer.
- Trial name
- ColoBEAM (NCT02751177)
- Testing
- KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA
- Where
- 11 sites in France
- Volunteers
- 236 people
- Sponsor
- Institut de Cancérologie de Lorraine
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
This phase II trial studies how well giving aflibercept together with combination chemotherapy works in treating patients with previously untreated colon or rectal cancer that is metastatic or locally advanced and cannot be…
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum
- Trial name
- NCT01652196
- Testing
- aflibercept, oxaliplatin, leucovorin
- Where
- 6 sites in United States
- Volunteers
- 56 people
- Sponsor
- John Hays
Colorectal Cancer Metastatic
ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer
The investigators hypothesize that the epigenetic agent valproic acid improve the activity of anti-EGFR agents, prevent and revert the emergence of EGFR resistance, in a rechallenge setting.
- Trial name
- VICTORIA (NCT06714357)
- Testing
- irinotecan, panitumumab, Valproic Acid (VPA)
- Where
- 8 sites in Italy
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute, Naples
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Colorectal Cancer
Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer
This study will determine if nimotuzumab provides a benefit in this type of cancer when given in combination with irinotecan. The study will test: How long any good effects last. How bad any side effects are.
- Trial name
- NCT00493857
- Testing
- Nimotuzumab Humanized Monoclonal Antibody, Nimotuzumab
- Where
- 12 sites in Canada
- Volunteers
- 100 people
- Sponsor
- YM BioSciences
Solid Tumor Malignancies, Colorectal Carcinoma
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383.
- Conditions
- Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
- Trial name
- NCT07030257
- Testing
- CP-383
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Tasca Therapeutics
Advanced Cancer, Advanced Solid Tumor
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer
- Trial name
- NCT05714553
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- NuCana plc